Login
Login
Register
Complete Your Profile
Change Password
Request a Password Reset
Download Documents
Download Documents
Get Help to Participate in This Tender
Change Password
For better security, update the account password.
The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | ADMINISTRATION FOR STRATEGIC PREPAREDNESS AND RESPONSE has issued a Tender notice for the procurement of a Bundibugyo Virus Outbreak Response Vaccines Bundivx Rrpv Consortium in the USA. This Tender notice was published on 18 Jun 2026 and is scheduled to close on 02 Jul 2026, with an estimated Tender value of Refer Document. Interested bidders can access detailed Tender information, eligibility criteria, and complete bidding documents by referencing TOT Ref No. 143513007, while the tender notice number is RRPV-26-13-BundiVx and Registering on the platform.
Procurement Summary
Country: USA
Summary: Bundibugyo Virus Outbreak Response Vaccines Bundivx Rrpv Consortium
Deadline: 02 Jul 2026
Posting Date: 18 Jun 2026
Other Information
Notice Type: Tender
TOT Ref.No.: 143513007
Document Ref. No.: RRPV-26-13-BundiVx
Competition: ICB
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_detailsLogin to see details Tender Details UPDATE: Question and Answers attached in documents. Date for submission revised to July 2, 2026. Documents
The Office of Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS) seeks to use the Rapid Response Partnership Vehicle (RRPV) Consortium, an enterprise partnership in collaboration with industry and academia to facilitate research and development activities as follows:
The purpose of this RPP is to advance investigational BDBV vaccine candidates leveraging the VSV vaccine platform, which has demonstrated single dose protection in past EBOV outbreaks.
Work includes manufacturing process development through production of initial current Good Manufacturing Practice (cGMP) Phase 1 clinical trial material (CTM), with a goal of up to 10, 000 doses. Early regulatory engagement will inform the critical-path IND-enabling nonclinical. The proposed approach must describe how any available platform efficiencies from prior or ongoing platform development and manufacturing to accelerate the path towards cGMP CTM production and IND submission under the U.S. FDA. Additional activities include a Phase 1 safety and immunogenicity trial as well as options for production of up to 100, 000 doses of cGMP CTM.
The end goal of this effort is (1) to produce cGMP CTM and meet regulatory requirements to enable use of investigational candidate(s) in a clinical trial for the ongoing 2026 BDBV outbreak and (2) to identify successful BDBV vaccine candidates for potential further development.
Please see the attachments for more information.
Questions are due June 16, 2026 by 12 p.m. Eastern. Proposals are due by June 26 at 3 p.m. Eastern.
Submission link: https://www.rrpv.org/solicitation/bundibugyo-virus-outbreak-response-vaccines-bundivx/
Notice ID: rrpv-26-13-bundivx
Department/Ind. Agency: health and human services, department of
Sub-tier: office of assistant secretary for preparedness and response
Office: barda - aspr / daappo / barda dcma
Product Service Code: an23 - health r&d services; health research and training; experimental development
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Inactive Dates: jul 17, 2026
Inactive Policy: 15 days after date offers due
Procurement Documents for USA
Access a comprehensive library of standard procurement documents specific to USA. Here, you'll find all the essential forms, guidelines, and templates required for tender applications and submissions in USA
Want To Bid in This Tender?
Get Local Agent Support in USA and 60 More Countries.
View Tenders By
Sign in with Google